102 related articles for article (PubMed ID: 23363981)
1. Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study.
Endo K; Saiki A; Yamaguchi T; Sakuma K; Sasaki H; Ban N; Kawana H; Nagayama D; Nagumo A; Ohira M; Oyama T; Murano T; Miyashita Y; Yamamura S; Suzuki Y; Shirai K; Tatsuno I
J Atheroscler Thromb; 2013; 20(5):494-502. PubMed ID: 23363981
[TBL] [Abstract][Full Text] [Related]
2. Probucol delays progression of diabetic nephropathy.
Endo K; Miyashita Y; Sasaki H; Ohira M; Saiki A; Koide N; Otsuka M; Oyama T; Takeyoshi M; Ito Y; Shirai K
Diabetes Res Clin Pract; 2006 Feb; 71(2):156-63. PubMed ID: 16009446
[TBL] [Abstract][Full Text] [Related]
3. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibitors and probucol suppress the time-dependent increase in urinary Type IV collagen excretion of Type II diabetes mellitus patients with early diabetic nephropathy.
Nishimura M; Sasaki T; Ohishi A; Oishi M; Kono S; Totani Y; Kato Y; Noto Y; Misaki S; Higashi K; Shimada F; Wakasugi H; Inoue K; Hoshiyama Y; Yamada K
Clin Nephrol; 2001 Aug; 56(2):96-103. PubMed ID: 11522101
[TBL] [Abstract][Full Text] [Related]
5. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
6. Telmisartan combined with probucol effectively reduces urinary protein in patients with type 2 diabetes: A randomized double-blind placebo-controlled multicenter clinical study.
Zhu H; Chen X; Cai G; Zheng Y; Liu M; Liu W; Yao H; Wang Y; Li W; Wu H; Lun L; Zhang J; Guan X; Yin S; Zhuang X; Li J; Liu Y; Zhou C
J Diabetes; 2016 Sep; 8(5):677-85. PubMed ID: 26458146
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy.
Lam KS; Cheng IK; Janus ED; Pang RW
Diabetologia; 1995 May; 38(5):604-9. PubMed ID: 7489845
[TBL] [Abstract][Full Text] [Related]
8. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.
Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
Diabetes Care; 2005 Nov; 28(11):2728-32. PubMed ID: 16249547
[TBL] [Abstract][Full Text] [Related]
9. Probucol ameliorates renal injury in diabetic nephropathy by inhibiting the expression of the redox enzyme p66Shc.
Yang S; Zhao L; Han Y; Liu Y; Chen C; Zhan M; Xiong X; Zhu X; Xiao L; Hu C; Liu F; Zhou Z; Kanwar YS; Sun L
Redox Biol; 2017 Oct; 13():482-497. PubMed ID: 28728079
[TBL] [Abstract][Full Text] [Related]
10. Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial.
Tan SMQ; Chiew Y; Ahmad B; Kadir KA
Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227659
[TBL] [Abstract][Full Text] [Related]
11. Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia.
Ohsawa M; Tamura K; Wakui H; Kanaoka T; Azushima K; Uneda K; Haku S; Kobayashi R; Ohki K; Haruhara K; Kinguchi S; Toya Y; Umemura S
Lipids Health Dis; 2015 Dec; 14():161. PubMed ID: 26645467
[TBL] [Abstract][Full Text] [Related]
12. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
[TBL] [Abstract][Full Text] [Related]
13. Probucol normalizes cholesteryl ester transfer in IDDM.
Bagdade JD; Stein E; Ritter MC
Diabetes Care; 1995 Oct; 18(10):1341-6. PubMed ID: 8721935
[TBL] [Abstract][Full Text] [Related]
14. Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers.
Ivory SE; Packham DK; Reutens AT; Wolfe R; Rohde RD; Lewis J; Atkins RC;
Nephrology (Carlton); 2013 Jul; 18(7):516-24. PubMed ID: 23506627
[TBL] [Abstract][Full Text] [Related]
15. [Effect of probucol on cardiac electrophysiology in anginal patients with hyperlipidemia and diabetes mellitus type II].
Anikin VV; Savin VV; Lupanov VP; Razygraev RA
Ter Arkh; 2000; 72(8):28-30. PubMed ID: 11019422
[TBL] [Abstract][Full Text] [Related]
16. Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia.
Endo K; Miyashita Y; Sasaki H; Ebisuno M; Ohira M; Saiki A; Koide N; Oyama T; Takeyoshi M; Shirai K
J Atheroscler Thromb; 2006 Feb; 13(1):68-75. PubMed ID: 16505594
[TBL] [Abstract][Full Text] [Related]
17. Effect of probucol on serum lipoprotein and apoprotein profiles in renal transplant patients.
Okubo M; Horii A; Kamata K; Takeuchi Y; Tsukamoto Y; Kobayashi N; Sato K; Kumano K; Endo T
Am J Kidney Dis; 1998 Feb; 31(2):356-9. PubMed ID: 9469511
[TBL] [Abstract][Full Text] [Related]
18. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein composition and HDL particle size distribution in women with non-insulin-dependent diabetes mellitus and the effects of probucol treatment.
Lane JT; Subbaiah PV; Otto ME; Bagdade JD
J Lab Clin Med; 1991 Aug; 118(2):120-8. PubMed ID: 1856575
[TBL] [Abstract][Full Text] [Related]
20. [Influence of low high-density lipoprotein cholesterolemia induced by probucol on the progression of coronary atherosclerosis].
Takahashi T; Hiasa Y; Harada S; Hosokawa S; Kato S; Tanimoto M; Kishi K; Ohtani R
J Cardiol; 1997 Aug; 30(2):67-72. PubMed ID: 9300286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
